Clinical Trials
47 trialsNAUTIKA1
Genentech, Inc.
TAPUR
American Society of Clinical Oncology
CONCERTO
University of Utah
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
CAPTUR
Canadian Cancer Trials Group
BOUQUET
Hoffmann-La Roche
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
CUPISCO
Hoffmann-La Roche
CheckMate142
Bristol-Myers Squibb
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NACHO-COBI
Baylor College of Medicine
ProTarget
Rigshospitalet, Denmark
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
ImmunoCobiVem
University Hospital, Essen
NEO-TIM
Fondazione Melanoma Onlus
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Alliance for Clinical Trials in Oncology
Using Tumor Models to Determine Treatments
University Health Network, Toronto
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
MEGALiT
Uppsala University Hospital
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
FINPROVE
Helsinki University Central Hospital
ECLIPSE
Queen Mary University of London
MODUL
Hoffmann-La Roche
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
DRUP
The Netherlands Cancer Institute
ROME
Fondazione per la Medicina Personalizzata
RadioCoBRIM
Technische Universität Dresden
BEACON
Peter MacCallum Cancer Centre, Australia
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Hoffmann-La Roche
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Hoffmann-La Roche
VECODUE
Fondazione Melanoma Onlus
NEO-VC
University Hospital Tuebingen
COWBOY
Radboud University Medical Center
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Grupo Español Multidisciplinar de Melanoma
CONVERCE
Center Eugene Marquis
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
ATELIER
Duke University
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium